Regulatory measures when implementing a new medical device into the cosmetic surgery industry. A case example: Macrolane

Abstract

Over the past two decades, the cosmetic surgery industry has experienced significant global growth. This expansion has piqued the interest of healthcare professionals and product manufacturers, both aiming to enhance accessibility to surgery for a broader demographic. This manuscript presents the case example of “macrolane” hyaluronic acid. This product was introduced into the cosmetic surgery industry in 2007 and then removed from the market in 2012 by the manufacturer. The manuscript also presents and discusses the regulatory measures that were enacted following the introduction of macrolane into the European market. Specifically, these regulatory measures involved: insurance, professional qualifications and training, clinician representatives, sanitation, safety, cooling-off periods, informed consent, and advertising. Within the manuscript, it is also highlighted that interests from different stakeholders can create tension in the cosmetic industry, specifically: 1. clients might ask for a product, and they need to be protected; 2. healthcare providers are seeking a profit, and are subject to liability; 3. product’s manufacturers, who are seeking to expand their market, need to pass through regulatory processes. In conclusion, we wish to raise awareness of the ethical issues related to the regulatory measures implemented by European regulatory agencies responsible for public health, especially during the launch of a new product. These ethical considerations encompass several aspects: establishing accountability for validating research authenticity, delineating the functions of compensatory systems, overseeing educational processes, and supervising advertising and marketing practices. It should be noted that the comprehensive exploration of these ethical matters falls outside the scope of this manuscript, as they pertain more to public affairs rather than the realm of cosmetic surgery itself. Therefore, the discourse on these matters is better suited for engagement by experts in political and social ethics. Level of Evidence: Level V, analysis of current regulatory practices.

Keywords

Cosmetic surgery / cosmetic medicine / regulation / ethics / macrolane

References

[1] BAAPS. Available from: https://baaps.org.uk/about/default.aspx [Last accessed on 22 Aug 2023]

[2] Gallager J. Plastic surgery booming in the UK. BBC News, London. Available from: http://wwwnews.live.bbc.co.uk/news/health-25986840 [Last accessed on 22 Aug 2023]

[3] Keogh Report: Review Committee (2013) Review of the regulations of cosmetic interventions: final report. National Health Service, London. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/192028/Review_of_the_Regulation_of_Cosmetic_Interventions.pdf [Last accessed on 22 Aug 2023]

[4] Griffiths D.Cosmetic surgery: regulatory challenges in a global beauty market.Health Care Anal2018;26:220-34.

[5] Hart-Davis A. Introducing the ten minute boob job. The Guardian, London. Available from: https://www.theguardian.com/lifeandstyle/2008/apr/13/women.healthandwellbeing1 [Last accessed on 22 Aug 2023]

[6] Hart-Davis A. My 30-minute scalpel-free boob jab turned into a year-long nightmare. Available from: https://www.dailymail.co.uk/femail/article-1163295/My-30-minute-scalpel-free-boob-jab-turned-year-long-nightmare.html [Last accessed on 22 Aug 2023]

[7] Thomas H. Ban on ‘lunchtime boob job’ jab. Available from: http://www.marieclaire.co.uk/life/health-fitness/ban-on-lunchtime-boob-job-jab-162778 [Last accessed on 22 Aug 2023]

[8] Siddique A. Cosmetic treatment industry given strict rules to protect vulnerable. The Guardian, London. Available from: https://www.google.com.hk/search?q=Siddique+A+%282016%29+Cosmetic+treatment+industry+given+strict+rules+to+protect+vulnerable.+The+Guardian%2C+London&sca_esv=559674773&hl=zh-CN&sxsrf=AB5stBinsfe3l8sFZX4Mv-AElsMDPFSXsg%3A1692866820408&source=hp&ei=BBnnZKCZF [Last accessed on 22 Aug 2023]

[9] Agerup B,Akermark C.Non-animal stabilized hyaluronic acid: a new formulation for the treatment of osteoarthritis.BioDrugs2005;19:23-30

[10] Heden P,von Wachenfeldt M,Fagrell D.Body shaping and volume restoration: the role of hyaluronic acid.Aesthetic Plast Surg2009;33:274-82.

[11] Trignano E,Armenti AF,Fallico N.Augmentation mammaplasty after breast enhancement with hyaluronic acid.Aesthet Surg J2015;35:NP161-8.

[12] Chaput B,Tristant H,Grolleau JL.[Macrolane^®, a too premature indication in breast augmentation. Focusing on current knowledge of the product].Ann Chir Plast Esthet2011;56:171-9.

[13] Crawford R.Macolane injections for breast enhancement in undiagnosed breast malignancy: A case report.JPRAS2011;64:1682-3

[14] Hedén P.Is hyaluronic acid gel a good option for breast augmentation?.Aesth Plast Surg2011;35:137.

[15] Nahabedian MY.Discussion: macrolane for breast enhancement: 12-month follow-up.Plast Reconstr Surg2011;127:861-2

[16] Siebert T,Vaysse C.The latest information on Macrolane™: its indications and restrictions.Ann Chir Plast Esthet2014;59:e1-1.

[17] Scaperrotta G,Tengvar M.Radiological assessment of the breast following enhancement with Macrolane: managing the challenges.Eur J Radiol2017;86:58-62.

[18] Trignano E,Pili N,Rubino C.Complications after breast augmentation with hyaluronic acid: a case report.Gland Surg2020;9:2193-7.

[19] Inami F,Handa K.Mammoplasty with fillers.Jap J Plast Reconstr Surg2006;49:1335-41

[20] Bonomi S,Salval A.Breast enhancement with macrolene: is it a reliable alternative to fat injection?.Plast Reconstr Surg2011;128:572e-3e.

[21] Grippaudo FR,Mattei M. Imaging evaluation and management of complications after macolane™ breast enhancement. Available from:https://www.academia.edu/13744188/Imaging_Evaluation_and_Management_of_Complications_after_Macrolane_Breast_Enhancement[Last accessed on 25 Aug 2023]

[22] Camenisch CC,Hedén P.Macrolane for volume restoration and contouring of the buttocks: magnetic resonance imaging study on localization and degradation.Plast Reconstr Surg2013;132:522e-9e.

[23] Claude O,Pigneur F.Treatment of HIV-infected subjects with buttock lipoatrophy using stabilized hyaluronic acid gel.Plast Reconstr Surg Glob Open2015;3:e466.

[24] Cerqua S.Macrolane (large particle biphasic hyaluronic acid) filler injection for correction of defect contour after liposuction.J Cosmet Laser Ther2013;15:228-30.

[25] Sito G,Santorelli A.Use of Macrolane VRF 30 in emicircumferential penis enlargement.Aesthet Surg J2013;33:258-64.

[26] Sinna R,Assaf N.Use of Macrolane to treat pectus excavatum.Ann Thorac Surg2012;93:e17-8.

[27] Hartmann V,Plaschke M,Nast A.Hand augmentation with stabilized hyaluronic acid (Macrolane™ VRF20 and Restylane® Vital, Restylane® Vital Light).J Dtsch Dermatol Ges2009;8:41-4.

[28] Chaput B,Crouzet C,Chavoin JP.[Macrolane®: a severe case of calf cellulitis after modeling injection].Ann Chir Plast Esthet2012;57:83-6.

[29] Chaput B,Chavoin JP,Garrido I.France prohibits the use of macrolane in aesthetic breast augmentation for reasons similar to criticisms of autologous fat grafting to the breast.Aesthetic Plast Surg2012;36:1000-1

[30] Garrido I,Gangloff D.[The adipose tissue transfer in the mammary parenchyma (part II): review of the literature on the carcinologic risks].Ann Chir Plast Esthet2011;56:49-58

[31] Chaput B,Crouzet C,Garrido I.Macrolane is no longer allowed in aesthetic breast augmentation in France. will this decision extend to the rest of the world?.J Plast Reconstr Aesthet Surg2012;65:527-8; discussion 528-9

[32] Goisis M,Guareschi M.Is hyaluronic acid gel a good option for breast augmentation?.Aesthetic Plast Surg2011;35:134-6; author reply 137

[33] Crawford R.Macrolane injections for breast enhancement in undiagnosed breast malignancy: a case report.J Plast Reconstr Aesthet Surg2011;64:1682-3.

[34] McCleave MJ.Is breast augmentation using hyaluronic acid safe?.Aesthetic Plast Surg2010;34:65-8; discussion 69-70

[35] CFR - Code of federal regulations title 21. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=812&showFR=1 [Last accessed on 22 Aug 2023]

[36] Kirkpatrick WN.The history of Trilucent implants, and a chemical analysis of the triglyceride filler in 51 consecutively removed Trilucent breast prostheses.Br J Plast Surg2002;55:479-89.

[37] Latham M.'If it ain't broke, don't fix it?': scandals, 'risk', and cosmetic surgery regulation in the UK and France.Med Law Rev2014;22:384-408

[38] Armitage G.Litigious culture - keep your counsel.J Res Nurs2005;10:487-9.

[39] McHale J. Children, cosmetic surgery, and perfectionism: a case for legal regulation. Routledge; 2015.pp.189-200. Available from: https://lawexplores.com/children-cosmetic-surgery-and-perfectionism-a-case-for-legal-regulation/ [Last accessed on 22 Aug 2023]